Similarly, the HIF1α inhibitor acriflavine impaired the stem cell potential of primary CML cells and murine BM cells transduced with BCR-ABL, thus suggesting that acriflavine may add therapeutic value to currently used tyrosine kinase inhibitors that target BCR-ABL by preventing CML relapse (88). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.